BTK and B-cell chronic lymphocytic leukemia: Inhibitors of the Bruton’s Tyrosine Kinase (BTK) and BCL2 (B-cell lymphoma 2) are two highly effective classes of agents in the management of patients with chronic lymphocytic leukemia (CLL) either as single agents or in combination.